Your browser is no longer supported. Please, upgrade your browser.
Settings
NKTR Nektar Therapeutics daily Stock Chart
NKTR [NASD]
Nektar Therapeutics
IndexS&P 500 P/E9.38 EPS (ttm)3.52 Insider Own0.60% Shs Outstand173.86M Perf Week5.52%
Market Cap5.75B Forward P/E- EPS next Y-2.70 Insider Trans-24.14% Shs Float172.77M Perf Month6.23%
Income658.60M PEG- EPS next Q-0.78 Inst Own94.70% Short Float10.26% Perf Quarter-17.43%
Sales1.18B P/S4.86 EPS this Y289.50% Inst Trans-1.32% Short Ratio10.60 Perf Half Y-13.00%
Book/sh9.40 P/B3.52 EPS next Y6.30% ROA29.70% Target Price69.91 Perf Year-59.65%
Cash/sh7.99 P/C4.14 EPS next 5Y-7.30% ROE37.60% 52W Range29.22 - 92.17 Perf YTD0.61%
Dividend- P/FCF8.57 EPS past 5Y36.30% ROI34.90% 52W High-64.12% Beta2.95
Dividend %- Quick Ratio14.80 Sales past 5Y51.60% Gross Margin98.00% 52W Low13.17% ATR1.51
Employees618 Current Ratio14.90 Sales Q/Q-25.80% Oper. Margin55.30% RSI (14)51.67 Volatility3.29% 4.22%
OptionableYes Debt/Eq0.00 EPS Q/Q-14.50% Profit Margin55.60% Rel Volume0.84 Prev Close33.47
ShortableYes LT Debt/Eq0.15 EarningsMay 08 AMC Payout0.00% Avg Volume1.67M Price33.07
Recom1.90 SMA200.97% SMA50-1.01% SMA200-22.90% Volume1,406,256 Change-1.20%
Mar-15-19Initiated SVB Leerink Mkt Perform $38
Dec-13-18Initiated Goldman Buy $62
Jun-11-18Downgrade H.C. Wainwright Buy → Neutral $54
Jun-04-18Reiterated H.C. Wainwright Buy $125 → $97
Apr-20-18Initiated Seaport Global Securities Buy $120
Apr-13-18Resumed Piper Jaffray Overweight $125
Apr-06-18Reiterated Mizuho Buy $89 → $103
Apr-02-18Resumed H.C. Wainwright Buy $125
Mar-02-18Reiterated Canaccord Genuity Buy $80 → $94
Jan-22-18Reiterated Mizuho Buy $45 → $89
Nov-13-17Reiterated Mizuho Buy $30 → $45
Nov-13-17Reiterated Canaccord Genuity Buy $35 → $50
Nov-09-17Initiated Canaccord Genuity Buy $35
Aug-17-17Initiated Evercore ISI In-line $20
Aug-07-17Initiated H.C. Wainwright Buy $31
Mar-20-17Reiterated ROTH Capital Buy $23 → $31
Nov-08-16Initiated Aegis Capital Buy
Sep-30-16Resumed Brean Capital Buy
Jan-07-16Reiterated Piper Jaffray Overweight $16 → $20
Mar-18-15Reiterated ROTH Capital Buy $21 → $19
May-23-19 05:29PM  Why this pain-killing opioid is spinning into a new company American City Business Journals
08:00AM  Nektar Announces the Launch of Inheris Biopharma, Inc. PR Newswire
May-22-19 07:29AM  Jim Cramer Weighs In On Nektar, L Brands And More Benzinga
May-21-19 07:06PM  Cramer's lightning round: McDonald's is 'one of the greatest stocks of our time' CNBC
May-16-19 04:07PM  6 Positions the Vanguard Health Care Fund Continues to Increase GuruFocus.com -7.55%
May-15-19 05:00PM  Nektar Therapeutics Announces Five Accepted Abstracts at 2019 American Society of Clinical Oncology's (ASCO) Annual Meeting PR Newswire
12:54AM  Edited Transcript of NKTR earnings conference call or presentation 8-May-19 9:00pm GMT Thomson Reuters StreetEvents
May-10-19 09:55AM  3 Small Drug Stocks Poised to Beat Q1 Earnings Estimates Zacks
May-09-19 04:08PM  This Biotech Stock Is Flying As Cancer Update, Opioid Approval Loom Investor's Business Daily +7.49%
02:33PM  Nektar (NKTR) Q1 Earnings & Revenues Beat, Decline Y/Y Zacks
07:00AM  What You'll Want to Know About Nektar Therapeutics' Q1 Earnings Results Motley Fool
12:23AM  Nektar Therapeutics (NKTR) Q1 2019 Earnings Call Transcript Motley Fool
May-08-19 05:45PM  Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:35PM  Nektar: 1Q Earnings Snapshot Associated Press
04:10PM  Nektar Therapeutics Reports Financial Results for the First Quarter of 2019 PR Newswire
May-07-19 03:31PM  Nektar Therapeutics Expected to Lose 69 Cents a Share TheStreet.com
09:35AM  What's in the Cards for Nektar (NKTR) This Earnings Season? Zacks
May-02-19 10:33AM  Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline Zacks
May-01-19 05:00PM  Nektar to Announce Financial Results for the First Quarter 2019 on Wednesday, May 8, 2019, After Close of U.S.-Based Financial Markets PR Newswire
Apr-28-19 05:00PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Apr-24-19 02:55PM  S&P 500 closes at record high, even as EPS growth stagnates Reuters
Apr-23-19 06:56PM  S&P 500 closes at record high, even as EPS growth stagnates Reuters
Apr-22-19 10:42AM  Were Hedge Funds Right About Souring On Nektar Therapeutics (NKTR)? Insider Monkey
Apr-12-19 03:26PM  These 3 Falling Knives Are Expected to Outperform GuruFocus.com
Apr-11-19 10:57AM  Analysts believe the stock market will set a record soon and these names are going to lead the way CNBC
Apr-03-19 04:38PM  GameStop falls while Dave & Buster's and Blue Apron rise Associated Press
11:50AM  A Look At Nektar Therapeutics's (NASDAQ:NKTR) Exceptional Fundamentals Simply Wall St.
Apr-02-19 03:00PM  Nektar Therapeutics Presents Preclinical Data on its Immuno-Oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019 PR Newswire
07:30AM  The Daily Biotech Pulse: FDA Nod For ADMA, Regulatory Setback For Apyx, Achieve Life Sciences Smoking Cessation Drug Trial Benzinga
Apr-01-19 04:43PM  Here are the typical employee salaries at Twitter, Salesforce, Yelp, Square, Zynga, Dolby and other tech companies American City Business Journals
04:15PM  Vaccibody AS and Nektar Therapeutics Present New Preclinical Data from their Immuno-Oncology Collaboration at the American Association for Cancer Research (AACR) Annual Meeting 2019 PR Newswire
Mar-30-19 09:30AM  Nektar (NKTR) Down 17.1% Since Last Earnings Report: Can It Rebound? Zacks
Mar-12-19 06:00AM  3 Stocks That Could Double Your Money Motley Fool
Mar-07-19 09:49AM  Stock Market News For Mar 7, 2019 Zacks
12:02AM  Edited Transcript of NKTR earnings conference call or presentation 28-Feb-19 10:00pm GMT Thomson Reuters StreetEvents
Mar-06-19 04:30PM  Nektar Therapeutics to Webcast Presentation at the Cowen and Company 39th Annual Health Care Conference PR Newswire -5.23%
06:28AM  Biotech Companies Slump Midday With FDA Chief Set to Leave Investing.com
Mar-05-19 08:15AM  Detailed Research: Economic Perspectives on Canopy Growth, Aimmune Therapeutics, Nektar Therapeutics, Workday, Workiva, and MAG Silver What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-04-19 08:00AM  BioXcel Therapeutics Announces Addition of Merck KGaA, Darmstadt, Germany, and Pfizer to Clinical Collaboration with Nektar for Development of Triple-combination Therapy in Pancreatic Cancer GlobeNewswire
Mar-01-19 10:48PM  Nektar Therapeutics Inc (NKTR) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com -5.94%
04:40PM  Nektar Therapeutics Presents Preliminary Immune Activation, Safety and Clinical Activity Data from the Ongoing Dose-Escalation Stage of the REVEAL Study at 2019 ASCO-SITC Meeting PR Newswire
12:14PM  Stocks making the biggest moves midday: Gap, Tesla, L Brands & more CNBC
09:26AM  Nektar (NKTR) Q4 Earnings Beat, NKTR-181 Review Extended Zacks
09:00AM  Nektar Therapeutics (NKTR) Q4 2018 Earnings Conference Call Transcript Motley Fool
Feb-28-19 04:10PM  Nektar Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results PR Newswire
03:00PM  Nektar Therapeutics to Host Earnings Call ACCESSWIRE
Feb-27-19 04:35PM  Nektar Therapeutics Announces Several Preclinical Data Presentations for its Immuno-oncology Pipeline Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2019 PR Newswire
02:03PM  Nektar Therapeutics Expected to Lose 55 Cents a Share TheStreet.com
07:28AM  7 Fundamental Plays for a Stock Picker Market Investopedia
Feb-25-19 05:00PM  Nektar Therapeutics to Webcast Conference Call for Analysts and Investors at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium PR Newswire
07:57AM  What's in the Cards for Nektar (NKTR) This Earnings Season? Zacks
Feb-21-19 04:30PM  Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2018 on Thursday, February 28, 2019, After Close of U.S.-Based Financial Markets PR Newswire -6.44%
12:10PM  Is Nektar Therapeutics (NASDAQ:NKTR) A Financially Strong Company? Simply Wall St.
Feb-18-19 01:49PM  Robbins Arroyo LLP: Nektar Therapeutics (NKTR) Officials Harmed the Company According to Shareholder Lawsuit Business Wire
Feb-17-19 09:12AM  3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys? Motley Fool
Feb-15-19 03:15PM  Nektar, Bristol combo drug shows signs of tumor reduction in bladder cancer patients Reuters
03:15PM  Clinical Data Presented from PIVOT-02 Study of Bempegaldesleukin (NKTR-214) with Nivolumab in Metastatic Urothelial Carcinoma Patients at the 2019 ASCO Genitourinary Cancers Symposium PR Newswire
07:35AM  Factors of Influence in 2019, Key Indicators and Opportunity within BCE, Nektar Therapeutics, Hormel Foods, Enanta Pharmaceuticals, MongoDB, and Regal Beloit New Research Emphasizes Economic Growth GlobeNewswire
Feb-14-19 05:24AM  8 Stocks That Can Lead in a 'Micro-Driven' Market Investopedia
Feb-12-19 03:02PM  9 U.S. Stocks That Are Coming to Life Again InvestorPlace -8.82%
08:04AM  The Daily Biotech Pulse: NASH Disappointment For Gilead, Xeris To Offer Shares Benzinga
Feb-11-19 05:14PM  Nektar Therapeutics to Webcast Conference Call with Urothelial Cancer Specialist for Analysts & Investors at the 2019 ASCO Genitourinary Cancers Symposium PR Newswire
01:49PM  Why Nektar Therapeutics Stock Gained 29% in January Motley Fool
Feb-05-19 02:25PM  Mizuho's 9 Best Biotech Stocks to Buy for 2019 Kiplinger
Jan-27-19 11:05AM  5 "Strong Buy" Stock Picks for 2019 (That Crashed in 2018) Kiplinger
Jan-26-19 10:05AM  Is Bristol-Myers Squibb a Bargain Now? Motley Fool
Jan-15-19 07:11AM  These beaten-down stocks are expected to roar back in 2019 MarketWatch +7.23%
Jan-14-19 08:46PM  Here's Why Nektar Therapeutics Gave Back 45% in 2018 Motley Fool
Jan-08-19 05:28PM  Here's Why Nektar Therapeutics Surged Today Motley Fool +11.09%
10:03AM  Top Gainers: Union Pacific, Motorcar Parts, Nektar Rally Into Close Investing.com
Jan-03-19 07:00AM  Today's Research Reports on Trending Tickers: Celgene and Nektar Therapeutics ACCESSWIRE -7.71%
07:00AM  ImaginAb Announces Immuno-Oncology License and Clinical Trial Collaboration with Nektar Therapeutics PR Newswire
Dec-31-18 12:50PM  DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:09AM  CLASS ACTION UPDATE for NKTR, FIT, WBT and XRAY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM  FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 GlobeNewswire
Dec-30-18 09:25PM  FINAL DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
Dec-29-18 08:00AM  NKTR FINAL DEADLINE: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important December 31 Deadline in Class Action NKTR GlobeNewswire
Dec-28-18 05:07PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
04:55PM  BioXcel Surges on Fast Track Designation to Agitation Drug Zacks
10:00AM  Pawar Law Group Reminds of Deadline in Securities Class Action Lawsuit Against Nektar Therapeutics - NKTR ACCESSWIRE
09:02AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 ACCESSWIRE
07:00AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of COST, NKTR, FIT and RBBN GlobeNewswire
Dec-27-18 09:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Nektar Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline NKTR ACCESSWIRE
12:02PM  MONDAY DEADLINE: The Schall Law Firm Announces it is Investigating Claims Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
09:59AM  SHAREHOLDER ALERT: ALGN NKTR FIT RBBN: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
08:30AM  Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, CA PR Newswire
Dec-26-18 01:45PM  IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE +7.72%
01:01PM  CLASS ACTION UPDATE for IGCC, NKTR and FIT: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 GlobeNewswire
09:38AM  KESSLER TOPAZ MELTZER & CHECK, LLP: Final Deadline Reminder for NEKTAR THERAPEUTICS Investors NKTR GlobeNewswire
Dec-25-18 10:07AM  Is Nektar Therapeuticss (NASDAQ:NKTR) CEO Pay Justified? Simply Wall St.
Dec-24-18 10:00AM  DEADLINE NEXT WEEK: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:01AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Nektar Therapeutics, Inc. (NKTR) and Lead Plaintiff Deadline - December 31, 2018 ACCESSWIRE
Dec-23-18 09:10PM  DECEMBER DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $250,000 to Contact the Firm ACCESSWIRE
02:00PM  IGCC, NKTR DOUBLE ALERT: Pawar Law Group Reminds Investors of Class Action Deadlines in IGCC NKTR ACCESSWIRE
01:00PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of APOG, IGCC, NKTR and FIT GlobeNewswire
Dec-21-18 01:03PM  SHAREHOLDER ALERT: COST NKTR TX APHA: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire -6.16%
12:35PM  IMPORTANT DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Nektar Therapeutics and Reminds Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
10:18AM  INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Nektar Therapeutics Business Wire
Dec-20-18 03:50PM  NKTR DEADLINE ALERT: Rosen Law Firm Reminds Nektar Therapeutics Investors of Important Deadline in Class Action NKTR GlobeNewswire
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology. It also develops NKTR-358, cytokine Treg stimulant, which is in Phase I to treat autoimmune diseases; NKTR-262, a toll-like receptor agonist that is in Phase I for solid tumors; and NKTR-255, which is in preclinical stage for immuno-oncology. In addition, the is developing ADYNOVATE and ADYNOVI for hemophilia A; MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; CIMZIA for crohn's disease, rheumatoid arthritis, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia associated with chronic kidney disease. Further, it is developing Macugen for age-related macular degeneration; Somavert for acromegaly; Neulasta for neutropenia; Dapirolizumab Pegol for systemic lupus erythematosus; PEGPH20 for pancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Halozyme Therapeutics, Inc.; Bristol-Myers Squibb Company; Baxalta Incorporated; and Eli Lilly and Company, as well as with Merck KGaA and Pfizer Inc to develop a therapy for treating pancreatic cancer. Nektar Therapeutics was founded in 1990 and is headquartered in San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ROBIN HOWARD WPresident & CEOMay 23Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 23Sale32.6933,3331,089,656295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Option Exercise7.2133,334240,338328,660May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 22Sale33.3833,3341,112,689295,326May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Option Exercise7.2133,333240,331328,659May 23 07:19 PM
ROBIN HOWARD WPresident & CEOMay 21Sale32.9333,3331,097,656295,326May 23 07:19 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerMay 16Sale31.371,92860,481164,463May 17 08:22 PM
ROBIN HOWARD WPresident & CEOMay 16Sale31.3713,383419,825295,326May 17 08:22 PM
Labrucherie Gil MSVP & Chief Financial OfficerMay 16Sale31.373,767118,171127,935May 17 08:20 PM
Nicholson JohnSVP & Chief Operating OfficerMay 16Sale31.374,077127,895166,578May 17 08:21 PM
Hora ManinderSVP Pharma Dev & Mfg OpsMay 16Sale31.372,44976,82594,694May 17 08:19 PM
Doberstein Stephen KSVP & Chief Scientific OfficerMay 16Sale31.373,461108,57295,913May 17 08:18 PM
GREER R SCOTTDirectorMar 08Option Exercise5.1410,00051,400145,083Mar 12 06:18 PM
ROBIN HOWARD WPresident & CEOFeb 21Option Exercise7.2133,333240,331342,042Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 21Sale41.0133,3331,366,986308,709Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 20Option Exercise7.2133,334240,338342,043Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 20Sale43.2033,3341,440,029308,709Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 19Option Exercise7.2133,333240,331350,924Feb 21 08:16 PM
ROBIN HOWARD WPresident & CEOFeb 19Sale42.3342,2151,787,161308,709Feb 21 08:16 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 19Sale42.391,80876,641166,391Feb 21 08:17 PM
Nicholson JohnSVP & Chief Operating OfficerFeb 19Sale42.393,822162,015170,655Feb 21 08:15 PM
Labrucherie Gil MSVP & Chief Financial OfficerFeb 19Sale42.393,592152,265131,702Feb 21 08:14 PM
Hora ManinderSVP Pharma Dev & Mfg OpsFeb 19Sale42.392,386101,14397,143Feb 21 08:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerFeb 19Sale42.393,310140,31199,374Feb 21 08:13 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Option Exercise10.6916,119172,312184,318Feb 06 07:17 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerFeb 04Sale42.1616,119679,577168,199Feb 06 07:17 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Option Exercise10.6963,000673,470237,477Jan 30 06:02 PM
Nicholson JohnSVP & Chief Operating OfficerJan 28Sale42.8263,0002,697,660174,477Jan 30 06:02 PM
Thomsen Jillian B.SVP & Chief Accounting OfficerNov 16Sale38.254,016153,612157,249Nov 19 06:15 PM
Nicholson JohnSVP & Chief Operating OfficerNov 16Sale38.255,982228,812174,477Nov 19 06:14 PM
ROBIN HOWARD WPresident & CEONov 16Sale38.2515,326586,220249,141Nov 19 06:14 PM
Hora ManinderSVP Pharma Dev & Mfg OpsNov 16Sale38.254,694179,54681,029Nov 19 06:12 PM
Labrucherie Gil MSVP & Chief Financial OfficerNov 16Sale38.256,515249,199106,544Nov 19 06:13 PM
Doberstein Stephen KSVP & Chief Scientific OfficerNov 16Sale38.254,524173,04378,734Nov 19 06:11 PM
Ajer Jeffrey RobertDirectorSep 20Sale56.766,750383,13015,750Sep 21 07:29 PM
Lingnau LutzDirectorSep 20Sale56.989,000512,82018,450Sep 21 07:32 PM
CHESS ROBERTDirectorSep 19Sale56.814,500255,645269,723Sep 21 07:31 PM
GREER R SCOTTDirectorSep 04Option Exercise5.1410,00051,400140,333Sep 06 07:12 PM
GREER R SCOTTDirectorSep 04Sale67.3910,000673,900130,333Sep 06 07:12 PM
WINGER DENNIS LDirectorAug 21Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 21Sale60.3015,000904,50042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Option Exercise14.2615,000213,90057,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 17Sale59.6215,000894,30042,750Aug 21 07:32 PM
WINGER DENNIS LDirectorAug 14Sale60.1517,1251,030,06942,750Aug 15 07:30 PM
WINGER DENNIS LDirectorAug 13Sale61.0417,1251,045,31059,875Aug 15 07:30 PM
ROBIN HOWARD WPresident & CEOJun 27Option Exercise10.6943,333463,230267,689Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 27Sale47.3943,3332,053,551224,356Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 26Option Exercise10.6943,333463,230267,689Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 26Sale49.3643,3332,138,917224,356Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 25Option Exercise10.6943,334463,240267,690Jun 27 07:42 PM
ROBIN HOWARD WPresident & CEOJun 25Sale51.8243,3342,245,568224,356Jun 27 07:42 PM
GREER R SCOTTDirectorJun 06Option Exercise5.148,60044,204138,933Jun 06 07:42 PM
WHITFIELD ROY ADirectorJun 06Buy59.373,400201,860177,000Jun 07 07:40 PM
GREER R SCOTTDirectorJun 06Sale60.008,600516,000130,333Jun 06 07:42 PM
CHESS ROBERTDirectorJun 05Option Exercise14.2610,000142,600284,223Jun 07 07:39 PM
WHITFIELD ROY ADirectorJun 05Buy55.221,60088,352173,600Jun 07 07:40 PM
CHESS ROBERTDirectorJun 05Sale55.1610,000551,600274,223Jun 07 07:39 PM
GREER R SCOTTDirectorJun 04Option Exercise5.141,4007,196131,733Jun 06 07:42 PM
GREER R SCOTTDirectorJun 04Sale61.991,40086,786130,333Jun 06 07:42 PM